My Cart

0 Item(s): $0.00

You have no items in your shopping cart.

Apixaban Half Life

Apixaban Half Life

About Apixaban Half Life

The pharmacokinetic properties of apixaban half life have been described in detail. In healthy male volunteers, apixaban was rapidly absorbed after oral administration, with a time to maximum plasma apixaban concentration of about 1 hour. The elimination half-life for apixaban in healthy subjects is approximately 12 hours.


apixaban half life is an anticoagulant (blood thinner) that reduces blood clotting and reduces the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

Apixaban is available under the following different brand names: Eliquis.

Dosages of Apixaban:

Dosage Forms and StrengthsTablets

  • 2.5 mg
  • 5 mg


Decreases risk of stroke/systemic embolism associated with nonvalvular atrial fibrillation.Prevention of deep vein thrombosis that may lead to pulmonary embolism following knee or hip replacement surgery.Treatment of and reduction in risk of recurrence of deep vein thrombosis (DVT) or pulmonary embolism .

Missed Dose

If a dose of ELIQUIS is not taken at the scheduled time, the dose should be taken as soon as possible on the same day and twice daily administration should be resumed. The dose should not be doubled to make up for a missed dose.


apixaban half lifeis a substrate of both CYP3A4 and P-gp. Inhibitors of CYP3A4 and P-gp increase

exposure to apixaban and increase the risk of bleeding. Inducers of CYP3A4 and P-gp decrease

exposure to apixaban and increase the risk of stroke.


There is no antidote to ELIQUIS. Overdose of ELIQUIS increases the risk of bleeding [seeWarnings and Precautions (5.2)].In controlled clinical trials, orally administered apixaban in healthy subjects at doses up to 50 mgdaily for 3 to 7 days (25 mg twice-daily for 7 days or 50 mg once-daily for 3 days) had noclinically relevant adverse effects.In healthy subjects, administration of activated charcoal 2 and 6 hours after ingestion of a 20-mdose of apixaban reduced mean apixaban AUC by 50% and 27%, respectively. Mean apparenthalf-life of apixaban decreased from 13.4 hours when apixaban was administered alone to 5.3hours and 4.9 hours, respectively, when activated charcoal was administered 2 and 6 hours afterapixaban, indicating that charcoal blocked the continued absorption of apixaban from the gut.


Bleeding (Aristotle Study)

  • Major (2.13%, warfarin 3.09%; P <0.0001)
  • Gastrointestinal (GI) (0.83%, warfarin 0.93%)
  • Intracranial (0.33%, warfarin 0.82%)
  • Intraocular (0.06%, warfarin 0.14%)
  • Fatal (0.06%, warfarin 0.24%)
  • Clinically relevant non-major bleeding (2.08%, warfarin 3.0%; P <0.0001)

Drugs affecting hemostasis

  • Aspirin and other antiplatelet agents
  • Other anticoagulants
  • Heparin
  • Thrombolytic agents
  • Selective serotonin reuptake inhibitors (SSRIs)
  • Serotonin norepinephrine reuptake inhibitors (SNRIs)
  • Nonsteroidal anti-inflammatory drugs (NSAIDs), when used chronically
  • Fibrinolytics

Know More About This Medicine and Buy Now :